CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned a consensus rating of "Hold" from the nineteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $74.94.

Several analysts have recently commented on CRSP shares. Royal Bank of Canada reiterated a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Barclays decreased their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a report on Wednesday, November 6th. Needham & Company LLC reiterated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Finally, StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday, November 7th.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,089 shares of the business's stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the business's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers lifted its position in CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company's stock valued at $2,324,000 after acquiring an additional 27,915 shares during the last quarter. CWM LLC lifted its position in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company's stock valued at $1,209,000 after acquiring an additional 22,199 shares during the last quarter. Capital Advisors Inc. OK lifted its position in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after acquiring an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new stake in CRISPR Therapeutics in the second quarter valued at $2,375,000. Finally, International Assets Investment Management LLC purchased a new stake in CRISPR Therapeutics in the third quarter valued at $1,825,000. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Down 7.1 %

NASDAQ:CRSP traded down $3.91 during midday trading on Tuesday, hitting $51.24. The stock had a trading volume of 1,955,772 shares, compared to its average volume of 1,496,142. CRISPR Therapeutics has a one year low of $43.42 and a one year high of $91.10. The stock has a 50-day moving average of $48.30 and a 200 day moving average of $51.58.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the business earned ($1.41) earnings per share. Sell-side analysts predict that CRISPR Therapeutics will post -5.14 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.